Description | MYLS22 is a first-in-class and selective inhibitor of optic atrophy 1 (OPA1) . MYLS22 can target endothelial OPA1 to curtail tumor growth and inhibits angiogenesis by impinging on NFkB activity and on angiogenic gene expression. It with anti-angiogenesis and anti-cancer activity. |
In vivo | MYLS22(10 mg/kg/天;肿瘤周围注射;每2天一次,连续14天)能够抑制小鼠的肿瘤生长。 |
molecular weight | 443.52 |
Molecular formula | C24H21N5O2S |
CAS | 306959-01-3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility | DMSO: 45 mg/mL (101.46 mM), Sonication is recommended. |
References | 1. Stéphanie Herkenne, et al. Developmental and Tumor Angiogenesis Requires the Mitochondria-Shaping Protein Opa1. Cell Metab. 2020 May 5;31(5):987-1003.e8. |